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ABSTRACT
Background and purpose: To report preliminary results of induction chemotherapy 
(IC) followed by neoadjuvant chemoradiotherapy (CRT) and surgery in locally 
advanced rectal cancer (LARC) patients.
Materials and methods: This is the preliminary evaluation of a phase II study. 
Patients with histologically proven rectal adenocarcinoma, stage II-III disease, 
who met the inclusion criteria, received induction FOLFOXIRI (5-FU, leucovorin, 
oxaliplatin and irinotecan) regimen in combination with targeted agents followed by 
CRT and surgery. Analysis of the first 8 patients was required to confirm the treatment 
feasibility before the accrual of 20 additional patients.
Results: The first 8 patients were evaluated. The median follow-up time was 
23 months. There were no treatment-related deaths. Trimodality strategy was well 
tolerated with high compliance and a good level of toxicity. There were no evidence 
of febrile neutropenia and any grade 4 adverse events were recorded. Three patients 
had pathologic complete response (pCR) and 1 patient had a nearly pCR (ypT1 ypN0).
Conclusion: Preliminary results are encouraging. FOLFOXIRI regimen plus 
targeted agents followed by CRT and surgery seems a safe approach. Longer follow-
up and higher number of patients are mandatory to confirm such findings.
INTRODUCTION
Despite validation of the trimodality treatment 
approach, including neoadjuvant 5-fluorouracil (5-FU)-
based chemoradiotherapy (CRT), surgery and adjuvant 
chemotherapy, distant metastasis remains a devastating 
issue of failure in locally advanced rectal cancer (LARC) 
management [1].
A recent meta-analysis concerning 3310 patients 
involved in four randomized trials showed a modest distant 
failure benefit (OR = 0.76; 95% CI, 0.60 to 0.97; p = 0.03) 
in adding oxaliplatin compared to standard 5-FU-based 
CRT [2]. But, definitive conclusions are still pending and 
the frequent development of distant metastasis in LARC 
continues to stimulate research community attention. The 
main consideration is the time window of approximately 4 
months from neoadjuvant CRT to systemic chemotherapy 
which may potentially facilitate distant micrometastasis 
growth. Shifting systemic chemotherapy as initial 
approach into the trimodality treatment paradigm could 
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represent a tangible option to target micrometastasis. 
Compared with postoperative CAPOX (capecitabine 
and oxaliplatin) regimen, induction CAPOX before 
neoadjuvant CRT achieved a more favorable compliance 
and toxicity profiles with similar pathologic complete 
response (pCR) rate, in several retrospective analysis 
and phase II randomized trials [3–4]. But these studies 
were not powered to draw any conclusions on survival 
outcomes. Therefore the risk of systemic spread remains 
a challenge.
Over the past decade, literature data reflects also 
a growing interest in defining a more effective systemic 
cytotoxic therapy. Year by year, Ras (KRas and NRas) 
and BRAF mutation status detection has become a crucial 
prognostic and predictive factor in colorectal patients [5–
6]. Nowadays, the national comprehensive cancer network 
(NCCN) recommends tumor tissue genotyped for Ras-
BRAF mutations in suspected or metastatic rectal cancers 
in order to tailor therapy and to confer – if any – benefit 
to patients [1].
Based on NCCN rectal guidelines and on the 
efficacy of the FOLFOXIRI (5-FU, leucovorin, oxaliplatin 
and irinotecan) regimen in combination with targeted 
agents demonstrated in wild-type KRas colorectal 
cancer patients [1, 7], we tested the utility of induction 
chemotherapy (IC) preceding neoadjuvant CRT and 
surgery resection in LARC. We report the preliminary 
results of a phase II study in order to provide an early 
opportunity to evaluate the efficacy of this new treatment 
sequence.
RESULTS
Patient characteristics
The first 8 patients were accrued between October 
2015 and September 2016. Table 1 lists the demographics 
of the study population. In total, 5 patients were classified 
as cT4 and 4 patients had tumor in the low rectum. There 
was only 1 patients with wild-type Ras-BRAF tumor 
Table 1: Patient characteristics
Characteristic n (%)
Age (years)
 median (range) 66 (44-70)
Gender
 Male 5 (62.5)
 Female 3 (37.5)
Smoke
 Yes 6 (75)
 No 2 (25)
Comorbidity
 none 5 (62.5)
 Arterial hypertension 3 (37.5)
Clinical tumor stage (T)
 T1-2 0
 T3 3 (37.5)
 T4 5 (62.5)
Clinical nodal stage (N)
 N0 0
 N1 2 (25)
 N2 6 (75)
Location from anal verge
 < 6 cm 4 (50)
 6 - 8 cm 4 (50)
 > 8 cm 0
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and he was treated with FOLFOXIRI regimen combined 
with panitumumab. The remainder (n = 7) received 
FOLFOXIRI regimen combined with bevacizumab.
Induction chemotherapy compliance and toxicity
Globally, 7 patients completed the planned cycles of 
IC. One patient underwent sudden cardiac death between 
the first and second cycle. The event was judged not 
related to study procedure. Patient history revealed arterial 
hypertension. In total, IC treatment was delayed because 
of toxic effect in one patient. Overall, grade 2 peripheral 
neurotoxicity (n = 2) and grade 3 neutropenia (n = 3) were 
observed. There were no evidence of febrile neutropenia 
and any grade 4 adverse events were recorded. The only 
other grade 3 toxic effects observed were oral mucositis 
(n = 1) and hyperkalemia (n = 1). No patients experienced 
grade 3 diarrhea.
Table 2: Acute toxicity in preoperative phase
Acute toxicity
IC Neoadjuvant CRT Global
G1-2 (%) G3-4 (%) G1-2 (%) G3-4 (%) G1-2 (%) G3-4 (%)
Allergy immunology
 Allergic reaction hypersensitivity - - - - - -
Constitutional symptoms
 Fatigue 4 (50) - 3 (37.5) - 7 (87.5) -
 Fever 1 (12.5) - 3 (37.5) - 4 (50) -
 Palpitation - - - - - -
Dermatology skin
 Rash desquamation 2 (25) - 2 (25) - 4 (50) -
 Radiation dermatitis - - 2 (25) - 2 (25) -
Gastrointestinal
 Disgeusia 2 (25) - - - 2 (25) -
 Oral mucositis - 1 (12.5) - - - 1 (12.5)
 Constipation 1 (12.5) - 2 (25) - 3 (37.5) -
 Diarrhoea 2 (25) - 1 (12.5) - 3 (37.5) -
 Nausea 4 (50) - - - 4 (50) -
 Vomiting - - - - - -
 Proctitis - - 2 (25) - 2 (25) -
 Haemorrhage rectum 2 (25) - - - 2 (25) -
Metabolism disorders
 Hyperkalemia - 1 (12.5) - - - 1 (12.5)
 ALT/AST increased 2 (25) - - - 2 (25) -
Neurology
 Neuropahy: sensory 4 (50) - 2 (25) - 6 (75) -
Pain
 Abdominal pain or cramping - - - - -
Renal genitourinary
 Dysuria - - 1 (12.5) - 1 (12.5) -
 Urinary frequency - - 1 (12.5) - 1 (12.5) -
Blood count
 Neutropenia 2 (25) 3 (37.5) - - 2 (25) 3 (37.5)
 Haemoglobin - - 1 (12.5) - 1 (12.5) -
Abbreviations: IC: induction chemotherapy; CRT: chemoradiotherapy; G: grade; ALT/AST: alanine transaminase/ aspartate 
transaminase.
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Neoadjuvant chemoradiotherapy compliance 
and toxicity
In total, 7 patients completed the programmed 
neoadjuvant CRT. As mentioned previously, one patient 
died during IC because of unrelated treatment cancer 
conditions. All patients received the RT prescribed total 
dose and no treatment interruptions were recorded. Due 
to IC-related toxicity, 4 patients received standard 5-FU-
based concomitant chemotherapy. No patients suspended 
chemotherapy definitely, and thus they received at least 
5 cycles of 5-FU with/without oxaliplatin. Acute toxicity 
incidences during IC and during CRT are shown in Table 
2. Interestingly, there were no severe acute complications 
during neoadjuvant CRT.
Trimodality treatment efficacy
After the end of CRT, four patients had their tumor 
shrinked more than 50% of the original measurement. 
Tumor size evaluation at diagnosis (cDim), post-IC 
(yDim), post CRT (yyDim) and detected in the operative 
specimen (pDim) is demonstrated in Figure 1. A clinical 
complete response was noted in one patient, whereas 
clinical tumor reevaluation was stable in 2 cases. 
Conservative surgery was performed in five patients and 
the remainder (n = 2) had a Miles surgery due to closeness 
to the anal verge. In total, 3 patients had pCR and 1 patient 
had a nearly pCR (ypT1 ypN0). None had positive radial 
margins. No peri-operative complications occurred. The 
median follow-up period was 23 months (range 18-28). 
At the time of the analysis, there were no treatment-related 
deaths. The estimated 1-year overall survival was 87.5% 
(0.387 - 0.981) (Figure 2). Among the 7 patients alive 
there was no initial evidence of local recurrence disease. 
One patient developed a distant relapse to the liver six 
months after surgery.
DISCUSSION
In the first stage of this two-stage design, 3 of the 
first 8 patients had pathologic complete response (pCR), 
which allowed the recruitment of 20 additional patients 
for the second stage. Globally, IC was well tolerated 
without negative impact – in term of interruption or major 
toxicities – on subsequent neoadjuvant CRT and resection. 
IC was given for up to four two-week cycles. There were 
Figure 1: Tumor size evaluation. Tumor size at diagnosis (cDim), after induction chemotherapy (yDim), after neoadjuvant 
chemoradiotherapy (yyDim) and detected in the operative specimen (pDim).
Figure 2: Overall survival.
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no grade 4 toxicities and no disease progression was 
seen during preoperative treatment phase. R0 resection 
was achieved in all patients who underwent surgery. To 
our knowledge, our experience represents the first series 
testing IC based on FOLFOXIRI regimen combined with 
targeted agents in LARC.
In the metastatic setting for colorectal cancer, 
FOLFOXIRI plus panitumumab or bevacizumab 
has shown promising clinical activity in Ras–BRAF 
wild-type patients [7, 8]. The combination of triplet 
chemotherapy and panitumumab or bevacizumab has 
shown equivalent or superior safety profile, as well as 
significant improvement in tumor response compared 
with the available literature data for two cytotoxic drugs (a 
fluoropyrimidine plus either oxaliplatin or irinotecan) with 
or without biologics [7]. Therefore, it was rational for us to 
investigate FOLFOXIRI plus targeted agents as systemic 
chemotherapy in LARC. Moreover, considering that pCR 
has been shown to be an efficacious surrogate endpoint 
for survival outcomes in LARC [9–10], understanding the 
effect of chemotherapy intensification, using FOLFOXIRI 
plus targeted agents, in a preoperative setting could be 
essential to properly improve pCR rate. A phase II clinical 
trial was designed to provide an early opportunity to 
evaluate the efficacy of this new strategy treatment. It 
serves as a platform to highlight opportunities to change 
LARC approach drug, with the goal to improve survival 
outcomes. Preliminary data were encouraging, although 
second stage is mandatory to interpret final results and to 
appropriately translate them into clinical practice.
There are several considerations that should be 
made. Firstly, an earlier intervention with systemic 
treatment could facilitate full dose chemotherapy 
administration and tumor regression. It has been estimated 
that in more than 30% of LARC patients adjuvant 
chemotherapy is omitted or is dose reduced, increasing 
the risk of systemic failures [10]. Theoretical advantage 
of IC may allow improvement of oxygenation and higher 
intramural concentration of cytotoxic drugs to the primary 
tumor. Currently, Ras-BRAF became a high-priority target 
also in advanced rectal patients given the prevalence of 
mutations in rectal adenocarcinoma [11]. In our study, 
testing Ras-BRAF mutation status was paramount 
in driving therapeutic decisions. Cetuximab and 
panitumumab – two anti-epidermal growth factor receptor 
(EGFR)- targeted antibodies – are effective in wild-type 
disease [12–13]. Patients with known Ras mutations had 
virtually no chance of benefit from anti-EGFR agents 
and thus they were not treated with cetuximab and 
panitumumab. In fact, exposure to anti-EGFR agents 
toxicities would not be justified. Bevacizumab, an anti-
angiogenic agent, was administred in Ras-BRAF mutated 
patients, because its efficacy did not depend on the Ras-
BRAF mutational status [11].
Secondly, our patient population, including all cases 
with cT3-4 disease and/or positive nodes but high-lying 
cT3N0, is representative of a poor prognosis group. At 
diagnosis, all patients underwent pelvic DW-MRI and 
definition of poor prognosis disease was based on several 
parameters, including clinical stage, size, distance from 
anal merge, sphincter infiltration, potential mesorectal 
fascia involvement and extra-mural or venous invasion. 
Each of these parameters allowed an improved prediction 
of worse outcome, reinforcing the fact that an aggressive 
systemic strategy could show promising clinical benefits 
in this setting of patients [14–16]. Our main worry was 
that patients would be not able to tolerate subsequent CRT. 
Actually, all patients received neoadjuvant CRT without 
interruption or dose-limiting toxicity.
Lastly, in LARC, no data are available about the 
association between IC and survival outcomes after the 
introduction of targeted agents. FOLFOXIRI plus targeted 
agents was repeated every 14 days for up to 8 cycles (four 
two-week cycles). Short induction period (4 months) was 
selected in order to explore the benefit from intensification 
of neoadjuvant CRT in the sequential strategy.
At present, we were unable to address LF, DF and 
median OS due to the short interval follow-up. Moreover, 
patients cohort was too small to provide firm conclusions. 
As a results of a favorable pCR profile in the first stage 
of the two-stage design, the trial would continue to the 
second stage with the accrual of additional patients.
MATERIALS AND METHODS
This phase II study is a research project coordinates 
by Department of Radiological Sciences, Oncology and 
Pathology, Policlinico Umberto I “Sapienza” University of 
Rome and it was approved by the” Sapienza” University of 
Rome (number 88569-140). All patients provided written 
consent to participate. The preliminary evaluation of the 
first 8 patients was required to confirm the feasibility 
of the treatment before completing the enrollment of 
additional 20 patients.
Patient selection
Selection criteria included patients with newly 
diagnosed histologically proven rectal adenocarcinoma 
within 12 cm from the anal verge, staged T3-4 tumor and/
or positive lymph-nodes, without any evidence of distant 
metastases; age ≥ 18 and ≤ 70 years; performance status 
≤ 2; adequate renal, hepatic and bone marrow function. 
Patients with high-lying cT3N0 disease were not included. 
Patients were also excluded in case of synchronous 
tumors, cardiovascular disease, history of neurological 
or psychiatric disorders, previous pelvis radiotherapy, 
contraindication to MRI examination.
Clinical examinations, including complete medical 
history and careful physical examination, as well as 
digital rectal examination, were combined with radiologic 
imaging to assess the precise local (T), regional nodal 
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(N), and distant (M) extent of the tumor. Radiologic 
imaging consisted of trans-rectal ultrasound, total body 
contrast-enhanced computed tomography (CT) and pelvic 
diffusion-weight magnetic resonance imaging (DW-MRI). 
Ras and BRAF mutational analyses was carried out on 
tumor biopsy.
Study treatment
All patients were treated with a multimodal 
treatment approach combining IC, followed by intensified 
neoadjuvant CRT and surgery.
IC consisted of four two-week cycles of the three-
drug regimen of leucovorin-modulated 5-fluorouracil, 
irinotecan, and oxaliplatin (FOLFOXIRI). Modifications 
have been made to standard FOLFOX with goals of 
increasing efficacy. Moreover, based on Ras-BRAF status, 
biologic agents, including bevacizumab, panitumumab or 
cetuximab, were added. Only patients with wild-type KRas 
genes received treatment with cetuximab or panitumumab. 
Due to potentially severe toxicity, patients aged older than 
70 years were excluded from the trial.
Therefore, IC consisted of four two-week cycles of 
the FOLFOXIRI regimen: irinotecan 165 mg/m2 day 1, 
oxaliplatin 85 mg/m2 day 1, leucovorin 200 mg/m2 day 
1, fluorouracil 2400 mg/m2 48-hour continuous infusion 
starting on day 1. In addition, cetuximab (400 mg/m2 
first infusion, 250 mg/m2 thereafter) or panitumumab (6 
mg/kg) or bevacizumab (5 mg/kg) were administered 
intravenously based on wild-type (cetuximab/
panitumemab) or mutated (bevacizumab) Ras-BRAF 
status. IC was left to the oncologists’ discretion, because 
of individual variations in the patient conditions and 
medical circumstances.
Two weeks from the end of last IC cycle, the 
assessment of local clinical response was performed by 
pelvic DW-MRI. Independent of clinical response, long 
course of intensified CRT was started within four weeks 
after IC completion. The detailed CRT protocol has been 
described previously [17–18]. Radiation therapy was 
delivered with intensity modulate technique at a dose of 45 
Gy (1.8 Gy/fr) to the whole pelvis plus 5.4/9 Gy (1.8 Gy/
fr) to the tumor volume with 6 to 15 MV energy photons. 
Concomitant chemotherapy consisted of OXP (50 mg/m2 
on the first day of each week of RT) and 5-FU (200 mg/
m2/5 daily continuous infusion).
Five weeks from the end of CRT, the assessment of 
local clinical response was performed by pelvic DW-MRI. 
Surgery was scheduled 7 to 9 weeks after the end of CRT 
treatment.
Study end point and statistics
Primary end point was the number of patients with 
pCR. pCR was defined as the absence of any residual 
tumor cells (ypT0) detected in the operative specimen, 
including the primary tumor area, the whole mesorectal 
fat, and the resected lymph nodes (ypN0).
Secondary end-points included toxicity and 
compliance with the regimen, tumor downstaging, 
R0 resection rate, surgical complications, sphincter 
preservation rate, local and distant failure rates, overall 
survival (OS). The assessment of local clinic response was 
performed by pelvic MRI and was based on investigator-
reported measurements according to Response Evaluation 
Criteria in Solid Tumors (RECIST) guidelines [19]. 
Toxicity scoring was performed using the Common 
Terminology Criteria for Adverse Events, Version 4.0 
[20]. OS was calculated in months from the date of 
diagnosis to the first event, including date of the last 
follow-up or death. Local failure (LF) and distant failure 
(DF) were defined as the time from diagnosis to local 
recurrence within the pelvis (LF) and distant metastasis 
(DF) occurrence. Standard descriptive statistics were used 
to evaluate the distribution of each factor. Continuous 
variables were presented as medians and interquartile 
range, and dichotomous variables were presented as 
counts and percentages.
The expected number of patients has been calculated 
according to the Simon’s two-stage design. Based on 
four large randomized phase III trials [21–24], the 
projected pCR rate after standard preoperative treatment 
is 15% and an absolute 20% improvement in pCR rate 
is deemed clinically significant. With an α error of 0.05 
and a power of 80%, the planned study would proceed as 
followed: after a first stage of 8 patients, if three or more 
patients with a ypT0N0 tumor are observed, accrual of 20 
additional patients will be achieved. If this condition is not 
met, the study will be stopped for futility. After the second 
step, if there are seven or more ypT0N0 tumor, it can be 
concluded that the rate of pCR is statistically significantly 
greater than that of literature.
Statistical analysis was carried out using R-Studio 
0.98.1091 software.
CONCLUSIONS
Our preliminary data supported the continued 
patients accrual. IC based on FOLFOXIRI regimen 
combined with targeted agents followed by neoadjuvant 
CRT and surgical resection is manageable and well 
tolerated. This combination of therapies will hopefully 
provide meaningful benefit. Surely, longer follow-up and 
final results are mandatory to assess if this trimodality 
strategy consistently translate to improved overall survival 
and metastasis free survival in LARC patients.
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